ferozsons-labs.com Open in urlscan Pro
209.182.201.6  Public Scan

Submitted URL: http://ferozsons-labs.com/
Effective URL: https://ferozsons-labs.com/
Submission: On October 28 via api from BY — Scanned from DE

Form analysis 1 forms found in the DOM

GET https://ferozsons-labs.com/

<form id="searchform" class="gensearch__form" action="https://ferozsons-labs.com/" method="get">
  <input id="s" name="s" value="" class="inputbox gensearch__input" type="text" placeholder="SEARCH ...">
  <button type="submit" id="searchsubmit" value="go" class="gensearch__submit glyphicon glyphicon-search"></button>
  <input type="hidden" name="lang" value="en">
</form>

Text Content

casibom deneme bonusu betforward-shart.com 1xbet-1xir.com Betturkey giriş
casibom Ferozsons Laboratories Limited – Ferozsons Laboratories Limited



 * 

 * LANGUAGES
    * English
    * اردو



 * About Us
   * History
   * Company Profile
   * Vision, Mission & Values
   * Message From CEO
   * Board of Directors
   * Contact Us
 * Partnerships
 * Product Portfolio
   * Product List
   * Pharmaceuticals
   * Medical Technologies
   * Exports
 * Investors
   * Company Profile
   * Governance
     * Corporate Briefing Session
       * Notice of Corporate Briefing Session 2023
       * Corporate Briefing Session Presentation 2023
     * Results of General Meeting
       * AGM 28-10-2023
     * Board of Directors
     * Shareholding Pattern
     * Name of Auditor & Legal Advisor
   * Video Message from CEO
   * Investor Relations
     * Online Form & Contact Person
     * Notices of General Meetings, Dividend / Bonus Declarations
     * Sitemap
     * Search
   * Media
     * Awards
     * Memberships
     * News & Updates
     * Website Last Updated
   * Election of Directors
     * Notice of Election of Directors
     * Detail of Submitted Proxies
     * Profile of Contesting Candidates
     * List of Shareholders
     * Proxy Form
     * Ballot Paper
   * Investor Information
     * PSX Symbol
     * Financial Ratios
     * Share Registrar
     * Free Float 30-09-2024
     * Code of Conduct
   * Shareholding Information
     * List of Non CNIC Shareholders
     * List of Unclaimed Dividends And Shares
     * Share Price
   * Financial Statements
     * Annual Reports
     * Interim Accounts
     * Financial Reports
   * Compliance Certificate
   * EHS Policy
   * Quality Policy
 * Patients
   * Disease Info
   * Drug Safety
   * Send Query
 * Physicians
 * CSR
 * Press & Media
   * Videos
   * Statement on Remdesivir
   * Statement on Lenacapavir
 * 




STATEMENT ON LENACAPAVIR



Ferozsons Laboratories Limited (Ferozsons) has entered into a non-exclusive
voluntary license agreement ...

Read More


OUR WORK IN HEPATOLOGY



Ferozsons Laboratories Limited has the distinction of being one of the leading
companies providing treatments ...

Read More

LATEST NEWS



Ferozsons Laboratories Limited collaborates with Rizq Foundation under its Omega
Initiative to combat hunger ...

Read More


 * ABOUT US

 * Profile of the Company
 * Board of Directors
 * Our Vision, Mission & Values Statement
 * History
 * Message from CEO


 * CONTACT US


 * PARTNERSHIPS


 * PATIENTS

 * Disease Info
 * Send Query
 * Drug Safety
 * 


 * PHYSICIANS


 * CSR


 * CAREERS


 * PRODUCTS PORTFOLIO

 * Pharma & OTC
 * Medical Technologies
 * Exports


 * INVESTORS

 * Awards
 * Election of Directors
 * Investor Information

--------------------------------------------------------------------------------


REGISTERED OFFICE

Ferozsons Laboratories Limited 197-A,
The Mall,Rawalpindi,Rawalpindi-42000
+92-51-4252150-53/55
+92-51-4252152-57
www.ferozsons-labs.com
info@ferozsons-labs.com


HEAD OFFICE

5 KM Sundar Raiwind Road, Raiwind,
Lahore, Pakistan
+92-42-36026700
+92-42-36026702
info@ferozsons-labs.com, info@bfbio.com


PHARMA FACTORY

P.O.Ferozsons, Amangarh - Nowshera
(Khyber Pakhtunkhwa)
+92-923-614295, 610159
+92-923-611302
info@ferozsons-labs.com

   







© Copyright Ferozsons Laboratories Limited 2004 - 2024 all rights reserved.
Designed & Developed by A2Z Creatorz
Design Update by David Torrone & Athanasios Anagnostopoulos



TOP